|
Bioactive formulation to treat osteoarthritis |
15/08/2017 |
SSA |
|
Biodistribution of CIGB-300 in cervical cancer (CERVIFARM-300-II Study) |
2013-01-18 |
CIGB |
|
Bioequivalence of diclofenac sodium retard |
04/10/2017 |
CIDEM |
|
Biograft-G in Dentistry |
11/03/2016 |
BIOMAT |
|
Biomarkers of exposition_Uchuva Dorada |
17/04/2018 |
kmunoz |
|
Biomodulin T in older adult for protection in events of local transmission of COVID-19 |
10/09/2020 |
BIOCEN |
|
Biomodulina T - IM - covid-19 - older adult |
29/05/2020 |
BIOCEN |
|
Biomodulina T - IM- covid-19 - older adultos - Phase IV clinical trial |
05/05/2020 |
BIOCEN |
|
CERVISEG-300-I Study |
2011-05-17 |
CIGB |
|
Challenge study to determine the protective efficacy of a single oral dose of the attenuated 638 strain. |
2008-09-12 |
FINLAY |
|
Change in Manufacture Process of Heberbiovac HB vaccine. |
2011-04-30 |
CIGB |
|
CIGB-258 at COVID-19 |
14/05/2020 |
CIGB |
|
CIGB-370 in patients with malignant tumors |
01/02/2016 |
CIGB |
|
CIGB500 in healthy volunteers |
2010-12-20 |
CIGB |
|
CIMAVax EGF in Lung Cancer in PHC. Phase IV |
05/08/2014 |
CIM |
|
CIMAvax-EGF in Bladder cancer |
11/08/2020 |
CIM |
|
CIMAvax-EGF vaccine Predictor Phase IV |
14/12/2015 |
CIM |
|
CITOPROT-III |
2009-02-26 |
CIGB |
|
Clinical Trial Heberbiovac HB vaccine Material Reference Batch |
2011-05-16 |
CIGB |
|
Clinical trial to evaluate the safety, reactogenicity and immunogenicity of the vax-TyVi vaccine in volunteers between 18 and 20 years of age. |
2008-07-29 |
FINLAY |
